HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?

Hims & Hers Health (HIMS) shares plunged over 30% after Novo Nordisk terminated their partnership for GLP-1 weight loss drugs, citing HIMS' use of compounded versions and concerns over sales tactics. This significant setback introduces near-term uncertainty for the direct-to-consumer health platform, despite HIMS' strong underlying revenue and earnings growth forecasts and its presence in the rapidly expanding GLP-1 market, which analysts project to exceed $150 billion by 2035, potentially offering long-term opportunities through alternative strategies.

Analysis

Hims & Hers Health (HIMS) experienced a significant stock price decline of over 30% following the termination of its GLP-1 drug supply partnership with Novo Nordisk. The catalyst for the partnership dissolution was Novo Nordisk's stated concerns regarding HIMS's use of custom-compounded semaglutide and its sales and promotional tactics, introducing notable operational and reputational risk. Despite this material setback and the resulting near-term uncertainty, HIMS maintains a strong underlying growth profile. Sales are forecast to increase 58.5% this year and 22.6% next year, with earnings projected to grow 36.5% annually over the next three to five years. The stock's valuation, at 41 times next year's earnings, remains at a premium, which is now weighed against the heightened risks. While the loss of a key supplier complicates its strategy, HIMS still operates within the vast GLP-1 market, which is projected to exceed $150 billion by 2035, suggesting potential alternative paths through other partnerships or continued compounding, albeit with increased scrutiny.

Key Decisions for Investors

• Given the sharp price drop and high volatility, investors should consider waiting for the stock to stabilize before initiating or adding to a position, as the immediate aftermath of such news can lead to further downside.
• Investors must now weigh the company's compelling long-term growth forecasts against the significant near-term uncertainties, including heightened regulatory risk and potential damage to its reputation following Novo Nordisk's public-facing concerns.
• For risk-tolerant growth investors, the selloff may present a long-term buying opportunity, but this requires accepting the high-risk, high-reward profile and closely monitoring the company's ability to secure a stable supply chain for its weight-loss products.